文献速递糖尿病

胰高血糖素抑制受损伴肝脏脂肪蓄积介导2型糖尿病患者血糖控制恶化

Impaired Glucagon Suppression Accompanied by Liver Fat Accumulation Mediated Worse Blood Glucose Control in Patients With T2D.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该横断面研究纳入604例2型糖尿病患者,用FibroScan Pro受控衰减参数(CAP)和肝脏超声定量肝脂肪,在180分钟口服葡萄糖耐量试验中评估胰高血糖素抑制,并对287例进行连续葡萄糖监测。MASLD组(CAP≥238 dB/m,n=414)各阶段胰高血糖素抑制均显著受损(均P<.05);CAP每增加1个标准差独立预测各阶段剂量依赖性抑制减弱(标准化β=0.183-0.303,P<.001);胰高血糖素抑制介导了肝脂肪对高血糖不良影响的14.9%至33.9%。

要点

  • MASLD组(CAP≥238 dB/m,n=414)各阶段胰高血糖素抑制均显著受损(均P<.05)。
  • CAP每增加1个标准差独立预测各阶段剂量依赖性抑制减弱(标准化β=0.183-0.303,P<.001)。
  • 胰高血糖素抑制介导了肝脂肪对高血糖不良影响的14.9%至33.9%。

核心结论

  • 2型糖尿病中肝脏脂肪蓄积与餐后胰高血糖素抑制缺陷强烈相关,尤其在男性,并介导了其对血糖控制不良影响的近三分之一。

研究设计与样本

  • 横断面研究,纳入604例2型糖尿病患者,用FibroScan Pro受控衰减参数(CAP)和肝脏超声定量肝脂肪,在180分钟口服葡萄糖耐量试验(0、30、60、120、180分钟)中评估餐后胰高血糖素抑制,其中287例接受连续葡萄糖监测。

主要发现

  • MASLD组(CAP≥238 dB/m,n=414)与非MASLD对照组(n=190)相比,各阶段胰高血糖素抑制均显著受损(均P<.05)。
  • CAP每增加1个标准差独立预测各阶段剂量依赖性胰高血糖素抑制减弱(标准化β=0.183-0.303,P<.001)。
  • 男性胰高血糖素抑制受损程度大于女性,且CAP相关失调更强。
  • 中介分析显示胰高血糖素抑制介导了肝脂肪对高血糖不良影响的14.9%至33.9%。

临床怎么用

  • 作者认为,靶向肝脏脂肪变性和胰高血糖素信号可能为2型糖尿病管理提供新的治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Metabolic dysfunction-associated steatotic liver disease is prevalent in type 2 diabetes (T2D) and exacerbates hyperglycemia, but its impact on postprandial glucagon suppression remains unclear. OBJECTIVE: To investigate the association between hepatic steatosis and impaired glucagon suppression during oral glucose tolerance tests (OGTTs), and to evaluate the mediating role of glucagon dysregulation in linking liver fat to glycemic control. METHODS: In this cross-sectional study, 604 patients with T2D underwent liver fat quantification via the FibroScan Pro controlled attenuation parameter (CAP) and liver ultrasound. Postprandial glucagon suppression was assessed during 180-minute OGTTs (0, 30, 60, 120, 180 minutes), with continuous glucose monitoring (CGM) in 287 participants. Glucagon suppression was calculated for early (0-30 minutes), late (30-180 minutes), and overall (0-180 minutes) phases. Multivariable regression and mediation analyses tested associations between CAP, glucagon dynamics, and CGM-derived glycemic profiles. RESULTS: Patients with T2D with MASLD (CAP ≥238 dB/m, n = 414) exhibited significantly impaired glucagon suppression compared to non-MASLD controls (n = 190) across all phases (all P < .05). Each 1-SD CAP increase independently predicted attenuated dose-dependent suppression in all phases (standardized β = 0.183-0.303, P < .001). Males showed greater suppression impairment than females and stronger CAP-associated dysregulation. Mediation analysis revealed that glucagon suppression mediated 14.9% to 33.9% of the adverse effects of liver fat on hyperglycemia. CONCLUSION: Liver fat accumulation in T2D is strongly associated with defective postprandial glucagon suppression, particularly in males, which mediates nearly one-third of its detrimental impact on glycemic control. Targeting hepatic steatosis and glucagon signaling may offer novel therapeutic strategies for T2D management.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Li S, Liu J, Yang C, et al. Impaired Glucagon Suppression Accompanied by Liver Fat Accumulation Mediated Worse Blood Glucose Control in Patients With T2D. J Clin Endocrinol Metab. 2025. PMID: 40406971. doi:10.1210/clinem/dgaf303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。